Arena nabs $65M payday; Clovis raising $170M; Apricus gets European OK for ED drug;

@FierceBiotech: Shire chief focuses on deal-making, trials with eye to revving up sales. More | Follow @FierceBiotech

 @JohnCFierce: Dynavax tumbles after FDA blocks shortcut on hepatitis B vax salvage operation. Article | Follow @JohnCFierce

@RyanMFierce: NIH for Health, BGI, Broad Institute, others ally to share Big Data in genomics (special lack of pharma players?) More | Follow @RyanMFierce

@EmilyMFierce: Scientists discover new antibacterial molecules to fight anthrax, TB. Report | Follow @EmilyMFierce

> Arena's ($ARNA) weight loss drug Belviq will finally go on sale tomorrow, triggering a $65 million milestone payment from Eisai. Story

> Right on the heels of a run-up in its stock price, Clovis Oncology ($CLVS) announced that it plans to raise $170 million from the sale of shares. Release

> Apricus Biosciences ($APRI) has won European approval for its erectile dysfunction drug Vitaros. Release

> BioLineRx has forged an out-licensing deal with China's Jiangsu Chia-tai Tianqing Pharmaceutical on the hepatitis C therapy BL-8030. The total potential deal value is $30 million. Release

Medical Device News

@FierceMedDev: Does J&J's latest metal hip lawsuit boost the number to 10,001? Article | Follow @FierceMedDev

@DamianFierce: Private equity firms are weighing bids for PRA as the CRO mulls an IPO. Story | Follow @DamianFierce

@MarkHFierce: Here's my first Berlin interview - it's about a nanotech tumor treatment company called MagForce AG. Cool stuff. Editor's corner | Follow @MarkHFierce

 @MichaelGFierce: New research further reveals nano-gold's delivery potential, safety risk. More | Follow @MichaelGFierce

> Malaysia anticipates OEM growth from U.S. device clients. Item

> CareFusion emerges as potential ICU bidder. Article

Pharma News

@FiercePharma: Sanofi joins GSK, MedImmune with 4-in-1 flu vaccine. Article | Follow @FiercePharma

@EricPFierce: French police are investigating death of 92--year-old man who took recalled Teva diuretic that may contain sedative. Story | Follow @EricPFierce

@CarlyHFierce: Valeant drops bid for Serbian generics maker. More | Follow @CarlyHFierce

> New deal part of Soriot's revised strategy to energize AstraZeneca. Item

> Patheon having 'Banner' year, with boost from Latin America. News

CRO News

> Celerion targets biologics, vaccine studies with Irish expansion. More

> PRA draws private equity interest as IPO pends. News

> Patheon finally turns a profit after $255M Banner deal. Article

> Boehringer eyes Chinese CMO market with biologics plant. Report

Biotech IT News

> AstraZeneca bolsters software systems for virtual R&D of neuroscience drugs. Article

> NIH, BGI, others ally to share Big Data in genomics. Item

> In latest acquisition, IMS Health scoops up Incential Software. Story

> Pharma giant Boehringer Ingelheim backs startup program Rock Health. More

> GenoSpace joins growing alliance for sharing translational research data. Article

And Finally… Investigators at the Scripps Research Institute say that the antibodies produced by cows suggest new ways to create new therapies for humans. Release

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.